All In Biotech

Drug Trial Radar · NCT03713619

This Was a Study of Efficacy and Safety of Two Secukinumab Dose Regimens in Subjects With Moderate to Severe Hidradenitis Suppurativa (HS).

A Randomized, Double-blind, Multi-center Study Assessing Short (16 Weeks) and Long-term Efficacy (up to 1 Year), Safety, and Tolerability of 2 Subcutaneous Secukinumab Dose Regimens in Adult Patients With Moderate to Severe Hidradenitis Suppurativa (SUNSHINE).

Last checked: Nov 20, 2026Latest source record: Oct 9, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 544 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

544

Actual

Start

Jan 31, 2019

Primary completion

Oct 1, 2021

Study completion Jul 26, 2022

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Oct 22, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study was to demonstrate superiority of secukinumab at Week 16, based on Hidradenitis Suppurativa Clinical Response (HiSCR) rates versus placebo, along with the maintenance of efficacy of secukinumab at Week 52 in subjects with moderate to severe HS. Moreover, this study also assessed the safety and tolerability of secukinumab.

Conditions

  • Hidradenitis Suppurativa

Interventions

  • secukinumabDrug

    Secukinumab 300mg every 2 or every 4 weeks

  • PlaceboDrug

    Placebo 300mg every 2 or every 4 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With Hidradenitis Suppurativa Clinical Response (HiSCR50)Time frame: 16 weeks

Locations

111 sites in 29 countries. Site status is shown where the registry gives one.

  • Novartis Investigative Site

    Birmingham, Alabama

  • Novartis Investigative Site

    Rogers, Arkansas

  • Novartis Investigative Site

    Anaheim, California

  • Novartis Investigative Site

    San Diego, California

  • Novartis Investigative Site

    Miami, Florida

  • Novartis Investigative Site

    Tampa, Florida

  • Novartis Investigative Site

    Glenview, Illinois

  • Novartis Investigative Site

    West Dundee, Illinois

  • Novartis Investigative Site

    Boston, Massachusetts

  • Novartis Investigative Site

    New Brighton, Minnesota

  • Novartis Investigative Site

    Saint Joseph, Missouri

  • Novartis Investigative Site

    Chapel Hill, North Carolina

  • Novartis Investigative Site

    Fairborn, Ohio

  • Novartis Investigative Site

    Pittsburgh, Pennsylvania

  • Novartis Investigative Site

    Charleston, South Carolina

  • Novartis Investigative Site

    Goodlettsville, Tennessee

  • Novartis Investigative Site

    Dallas, Texas

  • Novartis Investigative Site

    San Antonio, Texas

  • Novartis Investigative Site

    Buenos Aires, Argentina

  • Novartis Investigative Site

    Ciudad Autonoma de Bs As, Buenos Aires, Argentina

  • Novartis Investigative Site

    La Plata, Buenos Aires, Argentina

  • Novartis Investigative Site

    Phillip, Australian Capital Territory, Australia

  • Novartis Investigative Site

    Benowa, Queensland, Australia

  • Novartis Investigative Site

    East Melbourne, Victoria, Australia

  • Novartis Investigative Site

    Linz, Austria

  • Novartis Investigative Site

    Vienna, Austria

  • Novartis Investigative Site

    Brussels, Brussels Capital, Belgium

  • Novartis Investigative Site

    Sofia, Bulgaria

  • Novartis Investigative Site

    Stara Zagora, Bulgaria

  • Novartis Investigative Site

    London, Ontario, Canada

  • Novartis Investigative Site

    Peterborough, Ontario, Canada

  • Novartis Investigative Site

    Waterloo, Ontario, Canada

  • Novartis Investigative Site

    Pilsen, Czechia

  • Novartis Investigative Site

    Prague, Prague 1, Czechia

  • Novartis Investigative Site

    Bordeaux, France

  • Novartis Investigative Site

    Brest, France

  • Novartis Investigative Site

    Créteil, France

  • Novartis Investigative Site

    Lyon, France

  • Novartis Investigative Site

    Montpellier, France

  • Novartis Investigative Site

    Nantes, France

Showing 40 of 111 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.